Hepatocellular carcinoma

Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016/S0140-6736(11)61347-0

El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053/j.gastro.2011.12.061

Chen, 2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65

Chen, 2010, Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death, Gastroenterology, 138, 1747, 10.1053/j.gastro.2010.01.042

Morgan, 2004, Alcohol and hepatocellular carcinoma, Gastroenterology, 127, S87, 10.1053/j.gastro.2004.09.020

Qiu, 2009, A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004), Int J Cancer, 124, 443, 10.1002/ijc.23911

Bertuccio, 2017, Global trends and predictions in hepatocellular carcinoma mortality, J Hepatol, 67, 302, 10.1016/j.jhep.2017.03.011

Dyson, 2014, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016/j.jhep.2013.08.011

Kanwal, 2016, Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans, Clin Gastroenterol Hepatol, 14, 301, 10.1016/j.cgh.2015.08.010

Degasperi, 2016, Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease, Lancet Gastroenterol Hepatol, 1, 156, 10.1016/S2468-1253(16)30018-8

Schlesinger, 2013, Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort, Ann Oncol, 24, 2449, 10.1093/annonc/mdt204

Tsilidis, 2015, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ, 350, g7607, 10.1136/bmj.g7607

Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423

Marrero, 2005, Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol, 42, 218, 10.1016/j.jhep.2004.10.005

Bravi, 2017, Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev, 26, 368, 10.1097/CEJ.0000000000000252

Ioannou, 2013, The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection, Hepatology, 57, 249, 10.1002/hep.25800

Chang, 2016, Long-term effects of hepatitis B immunization of infants in preventing liver cancer, Gastroenterology, 151, 472, 10.1053/j.gastro.2016.05.048

Papatheodoridis, 2015, Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy, J Hepatol, 62, 956, 10.1016/j.jhep.2015.01.002

Singal, 2010, Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis, Clin Gastroenterol Hepatol, 8, 192, 10.1016/j.cgh.2009.10.026

Morgan, 2013, Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies, Ann Intern Med, 158, 329, 10.7326/0003-4819-158-5-201303050-00005

Reig, 2017, Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?, Semin Liver Dis, 37, 109, 10.1055/s-0037-1601349

Waziry, 2017, Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression, J Hepatol, 67, 1204, 10.1016/j.jhep.2017.07.025

Li, 2014, Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study, Hepatology, 60, 588, 10.1002/hep.27160

Chen, 2013, Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies, Gut, 62, 606, 10.1136/gutjnl-2011-301708

Nkontchou, 2012, Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis, Cancer Prev Res (Phila), 5, 1007, 10.1158/1940-6207.CAPR-11-0450

Simon, 2016, Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES, Hepatology, 64, 47, 10.1002/hep.28506

Schulze, 2016, Genetic profiling of hepatocellular carcinoma using next-generation sequencing, J Hepatol, 65, 1031, 10.1016/j.jhep.2016.05.035

Piñol, 2017, Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: biomarker study of the STORM phase III trial, J Hepatol, 66, S12, 10.1016/S0168-8278(17)30287-8

Sherman, 2014, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, 28, 783, 10.1016/j.bpg.2014.08.008

Croswell, 2010, Principles of cancer screening: lessons from history and study design issues, Semin Oncol, 37, 202, 10.1053/j.seminoncol.2010.05.006

Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 417, 10.1007/s00432-004-0552-0

Poustchi, 2011, Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?, Hepatology, 54, 1998, 10.1002/hep.24581

Singal, 2017, Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma, Gastroenterology, 152, 608, 10.1053/j.gastro.2016.10.042

Sarasin, 1996, Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016/S0002-9343(96)00197-0

Arguedas, 2003, Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis, Am J Gastroenterol, 98, 679, 10.1111/j.1572-0241.2003.07327.x

Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199

2012, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016/j.jhep.2011.12.001

Lok, 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease, Gastroenterology, 136, 138, 10.1053/j.gastro.2008.09.014

2016, EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004

Singal, 2009, Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther, 30, 37, 10.1111/j.1365-2036.2009.04014.x

Singal, 2013, Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?, Am J Gastroenterol, 108, 425, 10.1038/ajg.2012.449

Marrero, 2009, Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053/j.gastro.2009.04.005

Lok, 2010, Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma, Gastroenterology, 138, 493, 10.1053/j.gastro.2009.10.031

Zhang, 1999, Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer, J Med Screen, 6, 108, 10.1136/jms.6.2.108

Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9

Shen, 2012, Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study, Lancet Oncol, 13, 817, 10.1016/S1470-2045(12)70233-4

Berhane, 2016, Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients, Clin Gastroenterol Hepatol, 14, 875, 10.1016/j.cgh.2015.12.042

Santi, 2010, Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival, J Hepatol, 53, 291, 10.1016/j.jhep.2010.03.010

Trinchet, 2011, Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities, Hepatology, 54, 1987, 10.1002/hep.24545

Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002/hep.21966

Welch, 2010, Overdiagnosis in cancer, J Natl Cancer Inst, 102, 605, 10.1093/jnci/djq099

Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136/gut.2009.187286

Leoni, 2010, The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria, Am J Gastroenterol, 105, 599, 10.1038/ajg.2009.654

Khalili, 2011, Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization, J Hepatol, 54, 723, 10.1016/j.jhep.2010.07.025

Rimola, 2012, Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI, J Hepatol, 56, 1317, 10.1016/j.jhep.2012.01.004

Piana, 2011, New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases, J Hepatol, 55, 126, 10.1016/j.jhep.2010.10.023

Darnell, 2015, Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US, Radiology, 275, 698, 10.1148/radiol.15141132

Vilana, 2010, Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology, 51, 2020, 10.1002/hep.23600

Galassi, 2013, Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound, Liver Int, 33, 771, 10.1111/liv.12124

Tremosini, 2012, Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma, Gut, 61, 1481, 10.1136/gutjnl-2011-301862

Bruix, 2016, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma, Gastroenterology, 150, 835, 10.1053/j.gastro.2015.12.041

Forner, 2014, Prognosis prediction and staging, Best Pract Res Clin Gastroenterol, 28, 855, 10.1016/j.bpg.2014.08.002

Yau, 2014, Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 146, 1691, 10.1053/j.gastro.2014.02.032

Tsochatzis, 2014, Liver cirrhosis, Lancet, 17, 1749, 10.1016/S0140-6736(14)60121-5

Johnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200/JCO.2014.57.9151

Pinato, 2017, The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 66, 338, 10.1016/j.jhep.2016.09.008

Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016/S0140-6736(02)08649-X

Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156

Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047

Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857

Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016/S1470-2045(08)70285-7

Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (in press).

Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9

Kalogeridi, 2015, Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review, World J Hepatol, 7, 101, 10.4254/wjh.v7.i1.101

Sangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002/hep.24451

Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 57, 1826, 10.1002/hep.26014

Salem, 2016, Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 151, 1155, 10.1053/j.gastro.2016.08.029

Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6

Chow, 2017, Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: the SIRveNIB study, Proc Am Soc Clin Oncol, 35, 4002, 10.1200/JCO.2017.35.15_suppl.4002

Abou-Alfa, 2016, Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance), Proc Am Soc Clin Oncol, 34, 192, 10.1200/jco.2016.34.4_suppl.192

Kokudo, 2015, Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines), Hepatol Res, 10.1111/hepr.12464

Boleslawski, 2012, Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis, Br J Surg, 99, 855, 10.1002/bjs.8753

Roayaie, 2015, The role of hepatic resection in the treatment of hepatocellular cancer, Hepatology, 62, 440, 10.1002/hep.27745

Llop, 2012, Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors, J Hepatol, 56, 103, 10.1016/j.jhep.2011.06.027

Cescon, 2012, Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma, Ann Surg, 256, 706, 10.1097/SLA.0b013e3182724ce8

Berzigotti, 2015, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis, Hepatology, 61, 526, 10.1002/hep.27431

Ishizawa, 2008, Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma, Gastroenterology, 134, 1908, 10.1053/j.gastro.2008.02.091

Shiina, 2012, Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors, Am J Gastroenterol, 107, 569, 10.1038/ajg.2011.425

Wang, 2012, Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma, J Hepatol, 56, 412, 10.1016/j.jhep.2011.05.020

Takayasu, 2012, Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines, J Hepatol, 56, 886, 10.1016/j.jhep.2011.10.021

Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016/j.jhep.2012.01.008

Malagari, 2012, Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis, Cardiovasc Interv Radiol, 35, 1119, 10.1007/s00270-012-0394-0

Fuks, 2012, Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis, Hepatology, 55, 132, 10.1002/hep.24680

Han, 2015, Laparoscopic versus open liver resection for hepatocellular carcinoma: case-matched study with propensity score matching, J Hepatol, 63, 643, 10.1016/j.jhep.2015.04.005

Hasegawa, 2013, Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey, J Hepatol, 58, 724, 10.1016/j.jhep.2012.11.009

Lu, 2014, Recent advances in the prevention of hepatocellular carcinoma recurrence, Semin Liver Dis, 34, 427, 10.1055/s-0034-1394141

Lee, 2015, Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma, Gastroenterology, 148, 1383, 10.1053/j.gastro.2015.02.055

Bruix, 2015, Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Oncol, 16, 1344, 10.1016/S1470-2045(15)00198-9

Ferrer-Fàbrega, 2016, Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection, Hepatology, 63, 839, 10.1002/hep.28339

Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104

Sapisochin, 2017, Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches, Nat Rev Gastroenterol Hepatol, 14, 203, 10.1038/nrgastro.2016.193

Mazzaferro, 2009, Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016/S1470-2045(08)70284-5

Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563

Herrero, 2008, Liver transplantation in patients with hepatocellular carcinoma across Milan criteria, Liver Transpl, 14, 272, 10.1002/lt.21368

Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria, Gastroenterology, 143, 985, 10.1053/j.gastro.2012.05.052

Toso, 2015, Total tumor volume and α-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation, Hepatology, 62, 158, 10.1002/hep.27787

Mazzaferro, 2016, Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach, Hepatology, 63, 1707, 10.1002/hep.28420

Breen, 2015, Image-guided ablation of primary liver and renal tumours, Nat Rev Clin Oncol, 12, 175, 10.1038/nrclinonc.2014.237

Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016/j.jhep.2009.12.004

Yu, 2017, Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial, Gut, 66, 1172, 10.1136/gutjnl-2016-312629

Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097/01.sla.0000201480.65519.b8

Huang, 2010, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 252, 903, 10.1097/SLA.0b013e3181efc656

Feng, 2012, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 57, 794, 10.1016/j.jhep.2012.05.007

Cucchetti, 2013, Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol, 59, 300, 10.1016/j.jhep.2013.04.009

Forner, 2014, Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol, 11, 525, 10.1038/nrclinonc.2014.122

Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016/j.jhep.2006.10.020

Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Interv Radiol, 33, 41, 10.1007/s00270-009-9711-7

Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038/bjc.2014.199

Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J Clin Oncol, 34, 2046, 10.1200/JCO.2015.64.0821

Kudo, 2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial, Hepatology, 60, 1697, 10.1002/hep.27290

Lencioni, 2016, Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial, J Hepatol, 64, 1090, 10.1016/j.jhep.2016.01.012

Meyer, 2017, Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial, Lancet Gastroenterol Hepatol, 2, 565, 10.1016/S2468-1253(17)30156-5

Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002/hep.24644

Reig, 2013, Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design, Hepatology, 58, 2023, 10.1002/hep.26586

Lencioni, 2014, GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 68, 609, 10.1111/ijcp.12352

Cheng, 2013, Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200/JCO.2012.45.8372

Johnson, 2013, Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200/JCO.2012.48.4410

Zhu, 2015, SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200/JCO.2013.53.7746

Cainap, 2015, Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial, J Clin Oncol, 33, 172, 10.1200/JCO.2013.54.3298

Llovet, 2012, Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 18, 2290, 10.1158/1078-0432.CCR-11-2175

Bruix, 2017, Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies, J Hepatol, 67, 999, 10.1016/j.jhep.2017.06.026

Reig, 2014, Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib, J Hepatol, 61, 318, 10.1016/j.jhep.2014.03.030

Llovet, 2013, Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, 31, 3509, 10.1200/JCO.2012.47.3009

Zhu, 2014, Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, 312, 57, 10.1001/jama.2014.7189

Zhu, 2015, Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016/S1470-2045(15)00050-9

Rimassa, 2017, Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial, Proc Am Soc Clin Oncol, 35, 4000, 10.1200/JCO.2017.35.15_suppl.4000

Bruix, 2011, Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques, Hepatology, 54, 2238, 10.1002/hep.24670

Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132

Prieto, 2015, Immunological landscape and immunotherapy of hepatocellular carcinoma, Nat Rev Gastroenterol Hepatol, 12, 681, 10.1038/nrgastro.2015.173

El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2